Hixon Zuercher LLC Cuts Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Hixon Zuercher LLC decreased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,313 shares of the life sciences company’s stock after selling 216 shares during the period. Hixon Zuercher LLC’s holdings in Illumina were worth $1,215,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Versant Capital Management Inc lifted its holdings in Illumina by 292.9% during the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 246 shares in the last quarter. Industrial Alliance Investment Management Inc. acquired a new position in shares of Illumina during the 2nd quarter worth about $34,000. Massmutual Trust Co. FSB ADV lifted its stake in Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after buying an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new stake in Illumina in the 2nd quarter worth about $61,000. Finally, Mizuho Securities Co. Ltd. purchased a new stake in Illumina during the 2nd quarter worth approximately $63,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ILMN shares. TD Cowen raised their target price on Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a research report on Tuesday. Barclays lifted their target price on shares of Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Robert W. Baird increased their target price on shares of Illumina from $119.00 to $124.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Daiwa Capital Markets raised shares of Illumina from a “neutral” rating to a “buy” rating and raised their price target for the stock from $120.00 to $154.00 in a research note on Friday, August 16th. Finally, Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective for the company in a research note on Thursday, October 17th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Illumina has an average rating of “Moderate Buy” and an average price target of $161.50.

Illumina Trading Up 1.0 %

Shares of ILMN stock opened at $154.96 on Wednesday. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $156.66. The firm has a market cap of $24.69 billion, a PE ratio of -15.56 and a beta of 1.13. The company has a 50-day moving average of $136.87 and a two-hundred day moving average of $122.92. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.11 and a quick ratio of 0.86.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter last year, the firm earned $0.33 EPS. The firm’s revenue for the quarter was down 3.5% on a year-over-year basis. On average, analysts predict that Illumina, Inc. will post 3.62 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.